Company Insights - Shares of Moderna, Inc. (MRNA) rose 5.3% on February 13, indicating renewed investor interest in large-cap biotech names amidst a choppy broader market [1][5] - The increase in stock price reflects confidence in Moderna's underlying vaccine platform and its ability to maintain momentum beyond the initial pandemic-driven surge [2] - Moderna continues to advance its mRNA technology, developing updated vaccines and expanding its development pipeline, which reinforces its long-term growth narrative [2] Industry Trends - Broader sentiment toward the biotech space improved, with several healthcare names attracting fresh capital as investors sought to diversify portfolios and manage volatility [3] - Institutional buying and short-covering likely contributed to the stock's strength, as investors rewarded companies with established commercial products and visible research pipelines [4] - The 5.3% rally in MRNA reflects a recalibration in risk appetite, balancing caution about market conditions with confidence in innovative healthcare leaders [4]

Group 1: Metals Sector - Jefferies analysts raised price targets for gold and copper miners, indicating a bullish outlook on precious and base metals [2][9] - Newmont's target increased to $158 from $136 and Barrick Gold's target raised to $66 from $60 [2] - Mid-tier players like Alamos Gold and Endeavour Mining also saw target increases to $61 and C$112 respectively [2] Group 2: Travel Sector - Jefferies cut its price target for Expedia from $285 to $240, reflecting concerns over potential headwinds in the digital booking space [3][9] - The firm remains optimistic about the aviation recovery in North America, raising Air Canada's target to C$22 from C$18 [3] Group 3: Economic Data and Currency - Japan's Q4 2025 GDP growth was below analyst forecasts, leading to a dovish outlook for the Bank of Japan and pushing the EUR/JPY exchange rate above 181.50 [4][9] - Industrial Production remained flat at -0.1% month-over-month in December, but Capacity Utilization rebounded by 1.3% [5] Group 4: Corporate Developments - ByteDance is enhancing safeguards against unauthorized use of IP and likenesses in response to concerns over its Seedance 2.0 project [6][9] - Jefferies raised its target for Moderna to $37 from $30, indicating a stabilizing outlook for the biotech company [7] - TD Cowen analysts upgraded Magna International's price forecast from $58 to $75, signaling confidence in the automotive supplier's growth trajectory for 2026 [7]

Core Insights - MRNA has experienced a pullback to a low of $36.66, indicating a potential successful test of support near the rising 10-week moving average at $37.74, suggesting readiness for a bullish trend continuation [1] - The key resistance level is identified at $55.20, where multiple indicators converge, and breaking this level could lead to accelerated bullish momentum [2] - Long-term upside targets for MRNA include the 200-week moving average at $92.99, with an initial target potentially being the 38.2% Fibonacci retracement at $76.72 [3] Group 1 - MRNA fell to a low of $36.66 this week, indicating a successful test of support near the 10-week moving average at $37.74 [1] - The area around $55.20 is identified as a key resistance level, with several technical indicators reinforcing this [2] - The 200-week moving average at $92.99 is highlighted as a long-term upside target, with the potential for MRNA to reach the top side of the falling channel [3] Group 2 - The bullish reaction following the low suggests that the pullback may complete the first phase after a long-term breakout [1] - The confluence of indicators at $55.20 suggests that breaking this level could confirm a continuation breakout [2] - The analysis indicates that the 38.2% Fibonacci retracement at $76.72 may be reached before the 200-week moving average [3]

Moderna Reports a Narrower-Than-Expected Loss. The Stock Slips After Earnings. - Barron'sSkip to Main ContentThis copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.# Moderna Is Losing Less Money Than Expected. The Stock Jumps After Earnings.By [Nate Wolf]ShareResize---ReprintsIn ...

Core Insights - Moderna reported fourth-quarter results that exceeded expectations, with shares rising more than 8% intra-day on Friday [1] - The company posted a quarterly loss of $2.11 per share, narrower than analyst estimates of a $2.62 loss, and revenue reached $678 million, down 30% year over year [1] - For full-year 2025, Moderna generated revenue of $1.9 billion, representing a 40% decline from 2024, with a net loss of $2.8 billion or $7.26 per share [2] Financial Performance - Fourth-quarter revenue was $678 million, modestly above the consensus forecast of $662.84 million [1] - Full-year 2025 revenue was $1.9 billion, a 40% decline from 2024 [2] - Cash and investments totaled $8.1 billion at year-end 2025, down from $9.5 billion at the end of 2024 [2] Future Outlook - Moderna reaffirmed its goal of achieving up to 10% revenue growth in 2026, with approximately half expected from U.S. markets and half from international markets [3] - The company expects research and development expenses of approximately $3.0 billion and selling, general, and administrative expenses of about $1.0 billion for 2026 [4] - Year-end cash and investments for 2026 are projected to range between $5.5 billion and $6.0 billion [4] Pipeline Developments - Moderna reported full enrollment in its Phase 3 Norovirus trial, with data anticipated in 2026 [4] - The company also achieved full enrollment in its Phase 2 intismeran autogene study for muscle invasive bladder cancer [4] - The influenza vaccine filing has been accepted for regulatory review in the European Union, Canada, and Australia, but received a Refusal-to-File letter from the U.S. FDA [3]

Core Insights - The company achieved a significant financial turning point in 2025 by reducing operating expenses by $2.2 billion, exceeding original cost-reduction targets by over $1 billion [1] - Revenue performance in 2025 was attributed to the successful U.S. launch of MNEXT Spike, which captured 24% of the total retail market despite a decline in overall COVID demand [1] - The company expressed strong disappointment with the FDA's Refusal to File letter for the mRNA-1010 flu vaccine, citing unpredictable regulatory environments as a threat to U.S. innovation leadership [1] Strategic Focus - The company shifted its strategic focus toward long-term sovereign partnerships in the U.K., Canada, and Australia to provide stable, annualized revenue streams starting in 2026 [1] - The oncology narrative was advanced by completing enrollment in three late-stage INT studies (melanoma, renal cell, and bladder cancer), reinforcing the platform's multi-histology potential [1] Operational Efficiency - The company leveraged AI integration across the business to drive productivity while maintaining a disciplined $1.0 billion SG&A spend and expanding into new geographic markets [1]

Company Overview - Madna's shares have rallied after the company narrowed its fourth quarter loss and reiterated its 10% revenue growth target, despite a 30% year-over-year revenue decline for the quarter [1] - The company anticipates a revenue rebound in 2026, with revenue expected to be split equally between the US and international markets [1] Market Performance - Madna's stock has increased by approximately 32% over the past 52 weeks, outperforming the healthcare sector, which has faced challenges recently [3] - The stock moved 5% higher in a recent trading session, indicating positive market sentiment despite previous pullbacks [2] Sector Analysis - The healthcare sector is experiencing a rotation away from high-flying technology and AI stocks towards more defensive sectors like healthcare and consumer staples [4] - However, the healthcare sector is facing government and legislative risks, particularly related to public healthcare spending and vaccine regulations [5][6] Analyst Insights - Analysts have adjusted their price targets for Madna, with RBC raising its target from $25 to $30 and Jefferies from $30 to $37, suggesting a more favorable outlook [7] Technical Analysis - Recent trading activity shows that Madna's stock has not yet surpassed previous relative highs near $45, with notable highs around $48 and $52 [8] - The stock is currently closing above its shorter-term moving averages, indicating potential upward momentum [9] - Significant volume activity is noted between price levels of $33 to $35, with current trading closer to $40 to $42, suggesting potential for rapid price movements [11] Options Activity - Madna has seen outsized options activity, with a volume five times the 5-day average, totaling about 170,000 options traded [12][13] - The expected price move for February is approximately ±8.2%, indicating market volatility [14] - A notable bullish trade involved 14,400 call options at a $47 strike price, reflecting positive sentiment among traders [15]

U.S. equity markets extended their slide on Friday, February 13, 2026, as a deepening sell-off in the technology sector overshadowed a surprisingly cool inflation report. Despite data showing that price pressures are easing faster than economists anticipated, investor anxiety regarding the long-term profitability of artificial intelligence (AI) and a significant technical setback for the world’s largest company sent major indexes into the red for a second consecutive session.Major Market Indexes Performance ...

Core Insights - Moderna reported a loss of $2.11 per share in Q4 2025, which is an improvement compared to the Zacks Consensus Estimate of a loss of $2.60 and a loss of $2.91 in the same quarter last year [1][6] - Total revenues for the quarter were $678 million, exceeding the Zacks Consensus Estimate of $659.5 million, but reflecting a 30% decline year over year due to lower net product sales [1][3] - Year-to-date, Moderna's stock has increased by 26%, outperforming the industry growth of 18% [1] Financial Performance - Overall product sales decreased by 31% year over year to $645 million, primarily due to reduced sales volume of COVID-19 vaccines [3] - The company generated $33 million from grants, collaborations, licensing, and royalty revenues, marking an 18% increase year over year [4] - For the full year 2025, Moderna's total revenues were $1.94 billion, down 40% year over year, with a loss of $7.26 per share, which is an improvement from a loss of $9.28 per share in the previous year [7] Cost Management - Selling, general and administrative (SG&A) expenses were $308 million, down 12% year over year due to reductions in consulting and external services [5] - Research and development (R&D) expenses decreased by 31% to $775 million, reflecting prioritization and efficiency in clinical development [5] Future Guidance - Moderna expects total revenues to grow by up to 10% in 2026 compared to 2025 levels, with a revenue split nearly equal between domestic and international operations [8] - The company is targeting operating expenses of approximately $4.9 billion, including $3 billion for R&D and $1 billion for SG&A [8] - Capital expenditure is projected to be between $0.2 billion and $0.3 billion [8] - Moderna anticipates ending 2026 with cash and cash equivalents between $5.5 billion and $6.0 billion [9] Pipeline Developments - Moderna is developing over 30 mRNA-based investigational candidates across various clinical stages, including a late-stage study for a norovirus vaccine [10] - The company faced a setback when the FDA refused to review its filing for a seasonal flu vaccine due to inadequacies in the supporting study [11] - An important candidate in the pipeline is intismeran autogene, a personalized cancer therapy being evaluated in collaboration with Merck across multiple pivotal studies [12][13]

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...